Q2 EPS Estimate for Ultragenyx Pharmaceutical Cut by Analyst

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at Wedbush cut their Q2 2025 earnings estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, May 7th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of ($1.08) for the quarter, down from their previous forecast of ($1.02). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($4.37) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.82) EPS.

A number of other research firms have also recently commented on RARE. HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. JPMorgan Chase & Co. upped their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $90.93.

Ultragenyx Pharmaceutical Trading Up 1.2%

Shares of RARE stock traded up $0.42 during trading hours on Monday, reaching $35.26. 55,282 shares of the company's stock were exchanged, compared to its average volume of 825,384. Ultragenyx Pharmaceutical has a 1 year low of $29.59 and a 1 year high of $60.37. The stock has a market cap of $3.33 billion, a PE ratio of -5.57 and a beta of 0.34. The stock's fifty day moving average price is $36.45 and its two-hundred day moving average price is $41.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. During the same quarter last year, the firm earned ($2.03) earnings per share. The firm's quarterly revenue was up 28.0% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RARE. California State Teachers Retirement System increased its holdings in Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after acquiring an additional 268 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after purchasing an additional 294 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares during the last quarter. Finally, Xponance Inc. lifted its stake in Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after buying an additional 347 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. The trade was a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.